Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Cindy Devone-Pacheco

Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids

Reuters Staff  |  November 8, 2017

NEW YORK (Reuters Health)—Early oral bisphosphonate use is associated with a lower risk of fractures among oral-glucocorticoid users, researchers from Canada report. Bisphosphonates are commonly used for glucocorticoid-induced osteoporosis, but their efficacy has been established only in primary osteoporosis, where the mechanism of action of bone loss differs from that seen with glucocorticoid use. Dr….

Maine Governor Will Not Expand Medicaid, Ignoring Voters

Gina Cherelus  |  November 8, 2017

(Reuters)—Maine Republican Governor Paul LePage said on Wednesday he will not expand the state’s Medicaid program under Obamacare, ignoring a ballot initiative widely backed by voters, calling it “ruinous” for the state’s budget. Maine looked set to become the first state in the nation to expand Medicaid by popular vote. About 60% of voters in…

Ex-Pharma Exec Azar Is Top Choice to Run U.S. Health Agency

Yasmeen Abutaleb  |  November 8, 2017

WASHINGTON (Reuters)—Alex Azar, a former pharmaceutical company executive, is U.S. President Donald Trump’s top pick to run the Department of Health and Human Services, two sources with knowledge of the confidential process said on condition of anonymity on Wednesday. Azar served at Eli Lilly for a decade, including five years as president of its U.S….

U.S. Congress to Hold Hearing on Allergan Tribal Patent Deal

Jan Wolfe  |  November 3, 2017

(Reuters)—A U.S. House of Representatives subcommittee on Thursday called a November 7 hearing on the legitimacy of an agreement between drugmaker Allergan Plc and a Native American tribe intended to shield patents from administrative review. The House Judiciary Committee’s subcommittee on intellectual property, chaired by Republican Representative Darrell Issa of California, said in a statement…

AmerisourceBergen Expects Tumbling Generic Drug Prices to Settle

Anuron Kumar Mitra and Tamara Mathias  |  November 3, 2017

(Reuters)—AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon’s possible entry into the industry. The drug distributor ended its fiscal year with a quarterly loss as it set aside $575 million for legal costs for a…

Trump Panel Urges More Treatment Options to Fight Opioid Crisis

Toni Clarke  |  November 2, 2017

(Reuters)—A panel convened by U.S. President Donald Trump to tackle the opioid crisis called on Wednesday for more treatment programs, tighter prescribing guidelines and additional drug courts to help reduce overdose deaths. The commission, led by New Jersey Governor Chris Christie, said the recommendations would require funding by Congress but did not recommend an amount….

Obamacare 2018 Enrollment Clouded by Uncertainty under Trump

Yasmeen Abutaleb  |  November 1, 2017

WASHINGTON (Reuters)—As Americans begin signing up for Obamacare health insurance plans on Wednesday, experts expect reduced participation as a bitter political debate clouds the program’s future. Republicans in Congress have repeatedly failed to repeal and replace former President Barack Obama’s healthcare law, which they have said drives up costs for consumers and interferes with personal…

Puerto Rico Seeks Help as Medicaid Crisis Deepens after Maria

Roberta Rampton and Robin Respaut  |  November 1, 2017

WASHINGTON/SAN FRANCISCO (Reuters)—Puerto Rico, still reeling from Hurricane Maria, is asking the Trump administration and U.S. lawmakers for help in staving off a Medicaid crisis that has put a quarter of the island’s residents at risk of losing medical care. The territory, which has grappled for years with shortfalls in funding of its Medicaid healthcare…

New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

Jonathan Stempel  |  November 1, 2017

(Reuters)—New Jersey on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of contributing to the state’s opioid crisis through deceptive marketing to doctors and patients, including the elderly and the “opioid-naive.” Christopher Porrino, the New Jersey attorney general, faulted what he called a decade-long marketing campaign of “almost inconceivable callousness and irresponsibility, and said…

One Member’s Personal Story Illustrates How RheumPAC Can Help Underserved Children

Brett Smith, DO  |  November 1, 2017

Almost one year into my term on the ACR’s Political Action Committee, RheumPAC, I’m looking back and reflecting on what led me here. My early career was focused on learning the basics of clinical practice and building relationships with healthcare providers. Shortly after I completed my fellowship, I established goals to improve access to care…

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 28
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences